

1 **TITLE PAGE**

2

3 **Full Title:**

4 Proteomic profiling of the large vessel vasculitis spectrum identifies shared signatures  
5 of innate immune activation and stromal remodelling

6

7 **Short Title:**

8 Proteomic profiling in large vessel vasculitis

9

10 **Authors:**

11 Robert T. Maughan<sup>1,2\*</sup>, Erin MacDonald-Dunlop<sup>1\*</sup>, Lubna Haroon-Rashid<sup>3</sup>, Louise  
12 Sorensen<sup>3,4</sup>, Natalie Chaddock<sup>3</sup>, Shauna Masters<sup>5</sup>, Andrew Porter<sup>2</sup>, Marta Peverelli<sup>2</sup>, Charis  
13 Pericleous<sup>2</sup>, Andrew Hutchings<sup>6</sup>, James Robinson<sup>3</sup>, Taryn Youngstein<sup>2</sup>, Raashid A. Luqmani<sup>5</sup>,  
14 Justin C. Mason<sup>2‡†</sup>, Ann W. Morgan<sup>3,4‡</sup>, James E. Peters<sup>1‡</sup>

15

16 1. Department of Immunology and inflammation, Imperial College London, UK.

17 2. National Heart and Lung Institute, Imperial College London, UK

18 3. Leeds Institute of Cardiovascular and Metabolic Medicine, University of Leeds, Leeds, UK

19 4. NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds,  
20 UK.

21 5. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Science  
22 (NDORMs), University of Oxford, Oxford, UK

23 6. Department of Health Services Research and Policy, London School of Hygiene & Tropical  
24 Medicine, UK

25

26 \*joint first authors, ‡ joint senior authors, † deceased

27

28 **Correspondence to:**

29 r.maughan@imperial.ac.uk, a.w.morgan@leeds.ac.uk, or j.peters@imperial.ac.uk

30

## 31 **Abstract**

32

33 Takayasu arteritis (TAK) and giant cell arteritis (GCA) are the primary forms of large vessel  
34 vasculitis (LVV) and can result in serious cardiovascular morbidity. Improved understanding  
35 of the molecular basis of these diseases is required to develop novel biomarkers and targeted  
36 treatments. Moreover, it is unclear whether shared or distinct pathogenic processes underpin  
37 the LVV spectrum. To address this, we performed plasma proteomic profiling, quantifying 184  
38 plasma proteins using Olink immunoassays in two independent cohorts totalling 405  
39 individuals. In Cohort 1, comparison of patients with TAK (N=96) and large vessel-GCA (LV-  
40 GCA) (N=35) versus healthy controls (HCs) (N=35) revealed 52 and 72 significant differentially  
41 abundant proteins, respectively. Correlation with disease activity status identified novel TAK  
42 and LV-GCA disease activity markers. Cohort 2 consisted of patients presenting acutely with  
43 possible cranial GCA (C-GCA); C-GCA was subsequently confirmed (n=150) or excluded  
44 (n=89). 31 proteins were associated with C-GCA. Analyses stratified by temporal artery biopsy  
45 results revealed enrichment of the proteomic signal in biopsy-proven GCA, suggesting the  
46 presence of distinct endotypes within C-GCA. Cross-disease comparison revealed that active  
47 TAK, LV-GCA and biopsy-proven C-GCA had highly similar plasma proteomic profiles.  
48 Twenty-six proteomic associations were shared across all three groups including IL6,  
49 monocyte/macrophage related proteins (CCL5, CCL7, CSF1), tissue remodelling proteins  
50 (VEGFA, TIMP1, TNC) and proteins not previously linked to LVV (TNFSF14, IL7R). We also  
51 observed disease-specific associations including increased CXCL9 in LV-GCA and C-GCA  
52 but not in TAK and decreases in the extracellular matrix protein COMP in TAK but not in LV-  
53 GCA or C-GCA. Evaluation of publicly available transcriptomic data from LV-GCA aortic tissue  
54 revealed that 47 of the 112 proteins significantly altered in  $\geq 1$  LVV type had significantly altered  
55 mRNA expression in LVV aortic tissue. Similarities in LVV proteomic profiles suggest shared  
56 pathobiology involving innate immunity, particularly monocyte/macrophages, lymphocyte  
57 homeostasis and tissue remodelling processes. Our results highlight a signature of immune-  
58 stromal cross talk in LVV and identify potential novel therapeutic targets in this axis (e.g.  
59 TNFSF14). The correspondence of plasma signatures to tissue phenotype highlights the  
60 potential for non-invasive monitoring of arterial inflammation and injury.

61

## 62 **Introduction**

63

64 Takayasu arteritis (TAK) and giant cell arteritis (GCA), the most common forms of large-vessel  
65 vasculitis (LVV) in adults, are characterised by granulomatous arterial inflammation.  
66 Progressive damage to arterial walls typically results in stenotic remodelling with consequent  
67 tissue ischaemia and manifestations such as sight loss, stroke, myocardial infarction and limb  
68 claudication<sup>1</sup>. Despite phenotypic similarities, TAK and GCA have different demographics,  
69 particularly age of onset, and, to a lesser extent, they affect different arterial territories. TAK  
70 affects the aorta and its major branches, while classically GCA has been described as  
71 involving the cranial arteries (C-GCA) such as the temporal artery. However, following  
72 advances in non-invasive vascular imaging techniques, it became clear that the aorta and  
73 other large vessels are frequently affected in GCA, and some patients have a large vessel-  
74 type presentation (LV-GCA) with non-specific constitutional symptoms and/or limb  
75 claudication similar to TAK<sup>2,3</sup>. Frequent large-vessel involvement in GCA and similar  
76 histopathological changes has led to debate regarding whether TAK and GCA represent  
77 varying manifestations of the same disease<sup>4,5</sup>. This question has important implications for  
78 drug development and clinical trial design. However, such comparisons are currently limited  
79 by an incomplete understanding of the pathogenic underpinnings of these diseases and a lack  
80 of comparative molecular data across LVV phenotypes.

81

82 There are several important challenges in the clinical management of TAK and GCA. Both  
83 initial diagnosis and recognition of relapse may be delayed and are made more difficult by a  
84 lack of effective biomarkers<sup>6</sup>. Blood tests such as C-reactive protein (CRP) lack specificity  
85 while vascular imaging can be insensitive, particularly in glucocorticoid-treated patients, and  
86 impractical for frequent serial monitoring<sup>7,8</sup>. In the era before widespread access to ultrasound  
87 scans, the diagnosis of C-GCA was confirmed by performing a temporal artery biopsy. While  
88 considered the “gold standard” diagnostic test, the presence of skip lesions may lead to false  
89 negative results. A negative biopsy therefore does not exclude the diagnosis of GCA. Progress  
90 in the treatment of LVV, particularly the development of targeted biologic therapy, lags behind  
91 that of other rheumatic diseases. Accordingly, there is overreliance on long-term  
92 glucocorticoids to maintain disease control with resulting iatrogenic harm<sup>9,10</sup>. Thus, there is a  
93 need for better biomarkers and novel therapeutics to improve patient outcomes.

94

95 Proteomic profiling has the potential to address these challenges<sup>11</sup>. Proteins are the effector  
96 molecules of most biological functions and the targets of most drugs. Given the proximity of  
97 arterial tissue to the circulation, blood-based proteomics is likely to be informative in LVV.

98 Specifically, we hypothesised that the levels of inflammation- and cardiovascular-related  
99 proteins will provide a read-out of disease activity and arterial pathobiology in LVV patients  
100 and enable evaluation of molecular similarities and differences between GCA and TAK. To  
101 this end, we performed proteomic profiling of 184 circulating proteins in two independent  
102 cohorts that included 281 patients with TAK, LV-GCA or C-GCA. We identify protein signatures  
103 associated with each LVV type and with disease activity. Cross-disease comparison revealed  
104 a striking similarity between the proteomic profiles of active LVV types. Our data indicate the  
105 shared dysregulation of innate immune and tissue remodelling pathways and highlight the  
106 potential for therapeutics targeting immune-stromal cross-talk.

107

## 108 **Results**

109

110 To identify proteins associated with LVV and to evaluate the presence of shared or distinct  
111 molecular signatures across TAK, LV-GCA and C-GCA, we measured plasma levels of 184  
112 inflammation- and cardiovascular-related proteins (**Table S1**) in two independent cohorts  
113 using the Olink Target antibody-based proximity extension assay (PEA) (**Figure 1**). To provide  
114 a standardised nomenclature, we report proteins using the non-italicised HUGO gene symbol  
115 of the encoding gene.

116

### 117 **Shared plasma proteomic profiles in TAK and LV-GCA**

118 Cohort 1 included 96 TAK patients, 35 LV-GCA patients and 35 healthy controls (HCs) (**Table**  
119 **1**). Patient characteristics were typical for TAK and LV-GCA with regards to age and sex, with  
120 younger onset and greater female:male ratio in TAK. HCs were well matched in terms of  
121 demographics to the TAK patients. LV-GCA patients were older and had a higher proportion  
122 of individuals of White European ancestry. The patient samples analysed encompassed a  
123 broad range of disease activity, disease duration and treatment status, particularly in TAK  
124 where sample size was greater. Patients with active disease tended to have shorter disease  
125 durations and were receiving higher glucocorticoid doses, as might be expected (**Table S2**).  
126 In Cohort 1, 158 proteins (86%) passed quality control (QC) parameters (**Methods**) and were  
127 available for analysis.

128

129 Comparison of proteomic profiles between TAK patients and HCs identified 52 differentially  
130 abundant proteins (DAP), with 42 upregulated and 10 downregulated (**Figure 2A, Table S3**).  
131 Cross-referencing of our results to those of a previous study<sup>12</sup> which used a different proteomic  
132 platform demonstrated that many of our proteomic associations were novel (**Figure S1, Table**  
133 **S3**). We next compared LV-GCA to HCs, revealing 72 DAP, with 60 increased and 12

134 decreased (**Figure 2B, Table S4**). The proteomic changes in TAK and LV-GCA in comparison  
135 to HCs were highly similar; 40 proteins were significantly altered in both diseases and 85% of  
136 all proteins had directionally concordant changes compared to HCs (**Figure 2C**). Proteomic  
137 similarity of TAK and LV-GCA was also reflected in principal component analysis (PCA), with  
138 TAK and LV-GCA clustering together and separated from HCs (**Figure S2A**).

139

140 As expected, many upregulated proteins in TAK and LV-GCA indicated immune activation  
141 including cytokines, chemokines, and growth factors (**Figure S2B**). Plasma IL6, the pleiotropic  
142 cytokine of known importance to LVV pathogenesis<sup>13</sup>, was significantly upregulated in both  
143 TAK and LV-GCA (**Figure 2E**), together with liver-derived inflammatory proteins such as SAA4  
144 and FCN2. Prominent innate immune involvement in both TAK and LV-GCA was indicated by  
145 increased levels of neutrophil-derived proteins (S100A12, LCN2, DEFA1) and  
146 monocyte/macrophage activation and chemotactic factors (CSF1, CCL3, CCL5, CCL7,  
147 CCL14). Plasma levels of TNF (tumour necrosis factor), IL12B and IFNG were not significantly  
148 altered despite previous links to TAK pathogenesis<sup>14</sup>. In contrast, we observed large increases  
149 in OSM (oncostatin M) and TNFSF14 (LIGHT), cytokines not previously associated with LVV  
150 (**Figure 2E**). In addition to the dysregulation of immune-related proteins, we observed the  
151 upregulation of proteins with functions related to the extracellular matrix (TIMP1, MMP1,  
152 CST3, TNC), fibrosis (TGFB1) and angiogenesis (VEGFA, HGF, ANG, COL18A1) in both  
153 diseases, likely reflecting a signature of arterial injury and remodelling. Six proteins were  
154 consistently downregulated in both diseases, including IL7R, KIT, TNXB and THBS4 (both  
155 extracellular matrix (ECM) related glycoproteins), DPP4 (a glucose metabolism and T-cell  
156 activation factor) and CR2 (the complement C3d receptor).

157

158 To evaluate whether there were disease-specific effects, we performed a direct comparison  
159 of TAK versus LV-GCA, which revealed 6 significant DAP (**Table S5**). Visualising the relative  
160 abundance of these proteins in each group demonstrated that the dysregulation of these  
161 proteins appeared to be LV-GCA specific (**Figure S3A**). For example, in LV-GCA, but not  
162 TAK, CXCL9, CCL11 and CA3 levels were elevated compared to HCs. Similarly, CR2 and  
163 TNFSF11 (or RANKL) were significantly reduced in LV-GCA but not in TAK. Changes specific  
164 to TAK were less prominent, with no proteins that had significant changes in TAK versus both  
165 HCs and LV-GCA. However, we observed that FGF23 and IL17A were significantly increased  
166 in TAK compared to HCs but were not significantly increased in LV-GCA versus HC (**Figure**  
167 **S3B**).

168

## 169 Signatures of active disease in TAK and LV-GCA patients

170 To identify proteins associated with disease activity in TAK and LV-GCA, we next compared  
171 the proteomic profile of active and inactive patients within each disease. In TAK, 16 proteins  
172 were significantly altered in active disease, with 11 upregulated and 5 downregulated (**Figure**  
173 **3A, Table S6**). Upregulated proteins included neutrophil-related factors (S100A12, CXCL5  
174 CXCL1), liver-derived proteins (SAA4, CFHR5), ECM components (TNC, NID1, CRTAC1,  
175 COMP) and angiogenic factors (VEGFA, ANG), indicating innate immune activation and  
176 vascular remodelling (**Figure 3B**). To corroborate the results of the active versus inactive  
177 patient analysis and identify proteins whose levels vary with the degree of disease activity, we  
178 tested for association with the numerical ITAS2010 disease activity score<sup>15</sup>. 8 of the 158  
179 proteins measured were significantly correlated (adjusted  $P < 0.05$ ) with the ITAS2010 score  
180 (**Figure S4A & C**), and 7 of these 8 were differentially abundant in the active versus inactive  
181 analysis.

182  
183 Assessment of disease activity in TAK is currently based on the evaluation of clinical features,  
184 imaging, and clinical laboratory measures of inflammation, particularly CRP levels. However,  
185 CRP lacks both sensitivity and specificity for active TAK<sup>7</sup>. We found that 6 proteins (NID1,  
186 TNC, S100A12, CD274 (sPD-L1), DEFA1 and DPP4) were more strongly correlated with  
187 ITAS2010 than CRP. In addition, for the 20 active TAK patients who had normal CRP levels  
188 ( $< 5\text{mg/L}$ ), 12 (60%) had abnormal levels (defined as greater than the mean + 3 standard  
189 deviations of HCs) in one or more of the ITAS2010-associated proteins, indicating their  
190 potential added value as markers of disease activity (**Figure S4D**).

191  
192 In LV-GCA, 18 proteins were significantly associated with active disease, with 17 increased  
193 and 1 decreased (**Figure 3A, Table S7**). Although two proteins (CFHR5 and VEGFA) were  
194 increased in active disease in both LV-GCA and TAK, the LV-GCA activity signature was  
195 largely distinct to that of TAK (**Figure 3A**). A more prominent acute phase response was  
196 evident in active LV-GCA compared to TAK with large increases in IL6 and multiple liver-  
197 derived inflammatory proteins (MBL2, ST6GAL1, C2) (**Figure 3D**). There were also  
198 differences in the chemokines and other immunoregulatory proteins affected; CXCL5 and  
199 CXCL1 levels were not significantly changed in active LV-GCA (**Figure 3E**) but there were  
200 increases in the monocyte-attracting chemokines (CCL7, CCL14, CCL23) and the T-cell  
201 recruitment and activation factors (CCL18, GNLY, TIMD4). Lastly, there were activity-  
202 associated increases in remodelling associated proteins TIMP1, COL18A1 and NRP1 in LV-  
203 GCA but not TAK.

204

205 To determine whether proteomic differences persist despite clinical remission, we compared  
206 inactive TAK and LV-GCA patients to HC participants. This analysis identified 22 and 61 DAP  
207 in inactive TAK and LV-GCA, respectively, with 18 common to both diseases (**Figure S5A-C**,  
208 **Tables S8 & S9**). Examples of proteins which remained elevated in inactive disease include  
209 OSM, S100A12, TNFSF14 and AXIN1 (**Figure S5D**). Importantly, these proteins remained  
210 chronically elevated regardless of disease duration (**Figure S5E**), even in TAK patients who  
211 had withdrawn all treatment following durable remission (**Figure S5D**; median time off  
212 treatment 2 years [inter-quartile range, IQR: 1.5-5.1]). Thus, our data indicate that a proportion  
213 of the proteomic changes observed in TAK and LV-GCA patients represent persistent  
214 molecular derangements which do not normalise with clinical remission.

215

### 216 **Biopsy proven C-GCA has a distinct proteomic endotype**

217 We next performed proteomic profiling of an independent cohort (Cohort 2) of 239 patients  
218 presenting acutely with possible C-GCA, recruited to the TABUL study<sup>16</sup>. Blood samples were  
219 taken rapidly following initiation of high dose glucocorticoids; median treatment duration was  
220 2 [IQR: 1-4] days. All patients underwent both temporal artery biopsy (TAB) and ultrasound  
221 sonography (USS) and a diagnosis of C-GCA was subsequently confirmed or excluded (Not  
222 C-GCA). Patient characteristics were typical for suspected C-GCA, with the majority of cases  
223 being over 60 years old (87.4%) and a predominance towards female sex and White European  
224 ancestry (**Table 2**). 56 (37.3%) of patients diagnosed with C-GCA had a positive TAB, 78  
225 (52%) had an abnormal USS and 53 (35.3%) were negative for both TAB and USS with the  
226 diagnosis made on the basis of clinical features. Compared to Not C-GCA patients, C-GCA  
227 patients were slightly older (median age 4 years greater) and had higher ESR, CRP and  
228 platelet levels (**Table 2**). Proteomic profiling was performed using the same Olink platform.  
229 167 proteins (91%) passed QC parameters and data from a minimum of 225 patients were  
230 available for analysis (**Methods**).

231

232 Proteomic comparison of C-GCA patients (n=150) to Not C-GCA cases (n=89) revealed 31  
233 DAP (**Figure 4A, Table S10**). Further investigation revealed heterogeneity of these protein  
234 profiles within C-GCA patients and that differences compared to Not C-GCA cases were  
235 mostly driven by the TAB positive (TAB+) C-GCA patient subset (**Supplementary Methods**,  
236 **Figure S6**). In analyses stratified by TAB result, comparison of TAB+ C-GCA (n=56) to Not C-  
237 GCA identified 62 DAP (**Figure 4B, Table S11**), while only 1 DAP was identified in the TAB  
238 negative (TAB-) C-GCA (n=89) versus Not C-GCA comparison (**Table S12**). The increase in  
239 significant associations when limiting to biopsy-proven cases despite reduction in sample size  
240 and hence statistical power indicates that TAB+ C-GCA is enriched for proteomic signal, and

241 that the TAB- group were diluting this signal in the analysis of all C-GCA versus Not C-GCA.  
242 Comparison of the estimated  $\log_2$  fold changes ( $\log_2FC$ ) and protein abundances from the  
243 TAB+ and TAB- stratified analyses confirmed larger magnitudes of effect in the former (**Figure**  
244 **4D & 4F**). We additionally found that TAB+ C-GCA patients had higher levels of CRP, ESR,  
245 platelets and presence of polymyalgic symptoms compared to TAB- C-GCA patients (**Figure**  
246 **4C & Table S13**). Moreover, PCA of all proteins assayed indicated separation of TAB+ from  
247 TAB- C-GCA patients (**Figure S6C**). Together, these findings indicate that C-GCA can be  
248 stratified into biologically and clinically distinct subsets by TAB result.

249  
250 Further exploration of TAB- patients with hierarchical clustering revealed that while the large  
251 majority did not share the TAB+ associated signature, 18 TAB- patients were similar to TAB+  
252 patients (**Figure S7**). However, this pattern had no significant association with demographic  
253 or clinical parameters. Relatedly, the comparison of C-GCA TAB- patients who had abnormal  
254 USS (N=36) to Not C-GCA cases did not identify any significant proteins. Together, these  
255 results suggest that TAB rather than USS positivity more closely reflects the proteomic  
256 phenotype.

257  
258 The 62 proteins associated with TAB+ C-GCA patients suggest both innate and adaptive  
259 immune activation with dysregulation of cytokines, growth factors, chemokines and other  
260 immune-related proteins (**Figure 4E**). In a previous proteomic study<sup>17</sup>, five of these proteins  
261 were identified as significantly altered in C-GCA (**Figure S8 & Table S11**). Similar to TAK and  
262 LV-GCA, many proteins involved in innate immune function were upregulated including acute  
263 phase response mediators (IL6, MBL2, SAA4, CFHR5, ST6GAL1) and factors involved in  
264 neutrophil and monocyte migration and activation (CXCL1, CCL14, CCL7, S100A12, CSF1).  
265 Several chemokines involved in T- and B-cell recruitment were also increased (CXCL9,  
266 CXCL10, CXCL11, CCL18) together with altered levels of lymphocyte survival and  
267 proliferation factors (increased IL7, decreased: IL7R, KITLG, TNFSF11). In addition, increases  
268 in ECM (MMP1, TIMP1, TNC, LTBP2), fibrosis (TGFB1) and angiogenesis-related proteins  
269 (VEGFA, HGF, NRP1) were indicative of vascular remodelling. The downregulated proteins  
270 with the lowest p-values were SERPINA5 and DPP4 (**Figure 4F**). In secondary analyses, we  
271 did not identify any proteins that were significantly associated with cranial ischaemic  
272 complications or polymyalgic symptoms within C-GCA patients when analysed both as a  
273 single group and when separated by TAB result.

274



275 **Correlated proteomic changes in active TAK, LV-GCA and biopsy-proven C-GCA with**  
276 **IL6 and VEGFA identified as key hub proteins**

277 We next explored similarities and differences in the plasma proteomic signatures associated  
278 with each form of LVV. We considered the possibility that our results might be impacted by  
279 differences in study design. In Cohort 2, C-GCA patients were sampled with active disease at  
280 the time of diagnosis, whereas in Cohort 1, patients were sampled during both active and  
281 inactive disease over a range of disease durations. To mitigate against this, we re-analysed  
282 Cohort 1 restricting case samples to active disease only. These analyses revealed 68 and 69  
283 differentially abundant proteins for active TAK versus HCs and active LV-GCA versus HCs  
284 respectively, of which the majority had also been significantly altered in the corresponding  
285 previous analyses using all cases (80.9% and 81.6% respectively, **Tables S14 & S15**). We  
286 then compared the results of these TAK and LV-GCA analyses to the proteomic associations  
287 identified in the TAB+ C-GCA versus Not C-GCA comparison in Cohort 2.

288  
289 112 DAP were identified in one or more LVV type (subsequently referred to as LVV-associated  
290 proteins, **Figure 5A, Table S16**). Directional changes were highly similar with 74 (66.1%)  
291 having concordant changes (**Figure 5B**) and significant correlation between both TAK and  
292 LV-GCA profiles with that of TAB+ C-GCA (Pearson  $r$  0.49 and  $r$  0.69, respectively, both  
293  $P < 0.0001$ ). Twenty-six proteins (23.2%) were dysregulated in all three diseases and 33  
294 proteins (29.5%) were dysregulated in two. Of the 26 shared DAP, all had directionally  
295 concordant changes, including 20 upregulated and 6 downregulated proteins. We define these  
296 26 proteins as the 'pan-LVV signature' (**Table S16**). Upregulated proteins included IL6, acute  
297 phase proteins (SAA4, CFHR5, ST6GAL1), monocyte and neutrophil factors (S100A12,  
298 CSF1), monocyte and lymphocyte chemokines (CCL5, CCL7, CCL3, CCL18, CCL23) and  
299 TNFSF14. Also increased were proteins related to arterial remodelling including VEGFA,  
300 HGF, MMP1, TIMP1 and the ECM glycoprotein Tenascin C (TNC). Decreases included IL7R,  
301 KIT and KITLG, each involved in lymphocyte differentiation and proliferation, DPP4, CR2 and  
302 TNXB (another ECM tenascin).

303  
304 Using the GTEx tissue transcriptome database<sup>18</sup>, we explored the global tissue expression  
305 profile of each LVV-associated protein, defining enhanced expression as >4 fold higher than  
306 average tissue level as per Human Protein Atlas methodology<sup>19</sup>. 83 (74.1%) had enhanced  
307 expression in  $\geq 1$  tissue. The most represented tissues were liver, spleen and whole blood  
308 (**Figure S9**). 11 proteins had enhanced arterial expression including TNC, TIMP1, COL18A1  
309 and TNFRSF11B (OPG), thereby indicating the possibility of blood-based measurement of  
310 arterial biomarkers in LVV.

311

312 To infer relationships between proteins, we constructed two networks using the 74 proteins  
313 with concordant changes using i) annotated protein-protein interactions using String-db<sup>20</sup>  
314 (**Figure 5C**) and ii) co-expression (Pearson  $r \geq 0.6$ ) (**Figure 5D**). The network of annotated  
315 interactions identified IL6 and IL10 as the central hubs with connections to proteins with  
316 distinct functions including chemotaxis (e.g. CCL5, CCL3), angiogenesis (e.g. VEGFA, HGF)  
317 and tissue remodelling (e.g. MMP1, TIMP1, TGFB1). In the network constructed using protein  
318 co-expression data, TIMP1 and VEGFA displayed even greater connectivity, appearing as  
319 central nodes with edges connecting both to other remodelling-related proteins (e.g.  
320 COL18A1, NRP1) and multiple immune-associated proteins (e.g. CSF1, TNFSF14, CCL14).  
321 These networks indicate the coordinated regulation of immune and vascular remodelling  
322 processes, suggesting immune-stromal cross-talk in LVV.

323

324 The most prominent inter-disease differences were between TAK and LV-GCA  
325 profiles compared to TAB+ C-GCA (**Figure 5A**). In particular, the large increases in EIF4EBP1  
326 and AXIN1 observed in TAK and LV-GCA were not seen in C-GCA. Similarly, increases in the  
327 neutrophil proteins DEFA1 and LCN2 were observed exclusively in TAK and LV-GCA (**Figure**  
328 **5E**). There were also differences between LV-GCA and TAB+ C-GCA profiles compared to  
329 TAK which indicate some degree of divergence between diseases. For example, increases in  
330 CXCL9 and TIMD4 were seen only in the GCA groups while decreases in the ECM-related  
331 proteins COMP and THBS4 were only found in TAK (**Figure 5F**).

332

### 333 **Plasma proteomic signatures reflect LVV arterial tissue phenotype**

334 Plasma proteins arise not only from blood cells but also from a wide range of tissues and  
335 organs, including the vasculature which is in direct contact with the blood. We therefore sought  
336 to evaluate whether changes in patient plasma (**Figure 5A**) reflect the phenotype of arterial  
337 tissue affected by LVV. Using bulk RNA-seq data from a study which compared surgically  
338 resected aortic tissue of LV-GCA to non-inflammatory aortic aneurysms (NI-AA)<sup>21</sup>, we found  
339 that for 47 (42%) of the LVV-associated plasma proteins, the corresponding gene was  
340 differentially expressed in LVV arterial tissue (**Figure 6A, Table S17**). Moreover, the log<sub>2</sub>FCs  
341 of these 47 plasma proteins correlated with the log<sub>2</sub>FC of the corresponding gene in LVV  
342 tissue versus NI-AA (**Figure 6B**), and 28 (59.6%) had directionally concordant changes across  
343 the transcriptomic analysis of LVV arterial tissue and the plasma proteomic analyses of all the  
344 3 LVV types.

345

346 Using the blueprint and GTEx bulk RNA-seq datasets<sup>18,22</sup>, we explored the cell-type and  
347 arterial expression profile of the 47 genes/proteins dysregulated in both plasma and arterial

348 tissue (**Figure S10A**). Macrophage and neutrophil expressed genes/proteins made up the  
349 largest subset (34%); this included CCL7, CSF1, CXCL9 and CD146 which were increased  
350 in both tissue and plasma (**Figure 6C**). Genes/proteins expressed by non-immune stromal  
351 cells such as TNC, MMP1, TIMP1 and NRP1 were also prominent (**Figure 6D**). This latter  
352 cluster was enriched for genes of high arterial expression (GTEx) and could be useful as  
353 markers of arterial remodelling. The remainder were lymphocyte-derived (**Figure 6E**) or had  
354 mixed expression profiles. Of note, despite the significant decreases in plasma protein levels  
355 of DPP4, CR2 and IL7R in LVV, expression of the corresponding genes was significantly  
356 increased in LVV arterial tissue (**Figure S10B**), emphasising that there may be discordance  
357 of direction of effect in different tissue compartments. Overall, these findings indicate that  
358 plasma proteomic signatures can reflect aspects of LVV tissue phenotype and could provide  
359 a valuable non-invasive read-out of pathogenic processes occurring in diseased arteries.

360

## 361 **Discussion**

362

363 TAK and GCA are currently classified as separate diseases<sup>23,24</sup> but some investigators have  
364 proposed that they could represent varying manifestations of the same disease spectrum<sup>4,5</sup>.  
365 This debate has largely focused on phenotypic similarities, reflecting patterns of arterial injury<sup>3</sup>.  
366 Genome-wide association studies reveal differences in the genetic risk factors that predispose  
367 to TAK or GCA<sup>25</sup>. However, a key unanswered question is whether the molecular effector  
368 pathways acting in these diseases are shared or distinct. This information is critical for the  
369 rational selection of new therapeutic strategies that target specific proteins.

370

371 Here, we address this by comparing the plasma proteomic profile of TAK, LV-GCA and C-  
372 GCA. In 281 patients with LVV, we measured 184 inflammation- and vascular-associated  
373 proteins to characterise the plasma proteome of each major LVV type and evaluate changes  
374 associated with disease activity states. We found that the proteomic profiles associated with  
375 active TAK, LV-GCA and biopsy-proven C-GCA were similar and identified a 26-protein 'pan-  
376 LVV' signature common to all three groups. This signature primarily included proteins of  
377 immunological function, but it also comprised proteins arising from or acting on the stroma,  
378 indicative of arterial injury and/or repair. Some of these proteins have well-established roles  
379 in LVV (e.g. IL6 and VEGFA)<sup>13,14</sup>, but others have not been previously linked to LVV.

380

381 The signature reflected prominent innate immune activation, particularly with increases in  
382 several proteins related to monocyte and macrophage function. Importantly, co-expression  
383 analysis revealed coordinated regulation of such proteins (e.g. CSF1, CCL18, CCL14) with  
384 multiple proteins involved in tissue remodelling (e.g. VEGFA, TIMP1 and TGFB1) thereby

385 highlighting innate immune-stromal crosstalk in LVV. This is consistent with recent reports  
386 implicating pro-fibrotic macrophage subsets in the fibrotic and stenotic remodelling of arteries  
387 in TAK and GCA, cell types that are less affected by current treatments<sup>26,27</sup>. These findings  
388 underscore the importance of macrophages in TAK and GCA pathogenesis and illustrate the  
389 need for markers and therapeutics which target macrophages beyond pro-inflammatory  
390 functions alone.

391

392 We also observed evidence for adaptive immune involvement, with changes in lymphocyte-  
393 related proteins like IL7R and TNFSF14. Plasma IL7R was decreased in all LVV groups, and  
394 its ligand IL7 was significantly increased in TAK and C-GCA. IL7 is essential for T-cell  
395 development and homeostasis whilst soluble (sIL7R) potentiates IL7 activity by enhancing  
396 bioavailability<sup>28</sup>. The pattern observed is similar to findings in ANCA-associated vasculitis and  
397 tuberculosis infection but contrasts with rheumatoid arthritis and lupus where sIL7R levels are  
398 increased<sup>29-31</sup>. As another example, TNFSF14 (LIGHT) was prominently elevated. TNFSF14  
399 acts as a T-cell costimulatory factor and triggers T-cell activation and proliferation<sup>32</sup>. TNFSF14  
400 promotes systemic immunopathology, as demonstrated by transgenic animals with  
401 constitutive TNFSF14 expression in T-cells<sup>33</sup>. Moreover, TNFSF14 can also act on non-  
402 haematopoietic structural cells including fibroblasts, endothelial and smooth muscle cells to  
403 drive tissue fibrosis<sup>34</sup>. Consistent with this, our co-expression network analysis identified an  
404 edge connecting TNFSF14 to VEGFA, a central hub node. Current treatment strategies in  
405 LVV are limited to suppression of inflammation and do not target fibrosis directly. Thus,  
406 TNFSF14 antagonism may be a novel therapeutic approach in LVV that provides dual targeting  
407 of both the immune response and the consequent stromal reaction.

408

409 Lastly, the signature included tissue remodelling proteins expressed by immune cells (e.g.  
410 VEGFA) or stromal cells (e.g. TNC, TIMP1, MMP1); the latter may represent useful markers  
411 of arterial damage independent of inflammation. Increased plasma TNC in LVV is relevant  
412 given its enrichment in normal arteries and increased expression in arteries affected by LVV.  
413 TNC is an ECM protein primarily expressed by fibroblasts at sites of tissue damage where it  
414 supports repair. It gained interest as a candidate marker of vascular injury, but its levels are  
415 also elevated in other disease states<sup>35</sup>. Although its lack of specificity may preclude its use as  
416 a diagnostic marker, TNC and other ECM proteins could be useful for monitoring arterial injury  
417 during follow-up and should be evaluated in longitudinal studies.

418

419 Despite the overall similarity in LVV proteomic profiles, we identified differences which suggest  
420 some immunological divergence between diseases. For example, the chemokine CXCL9 was  
421 higher in LV-GCA and C-GCA compared to TAK. CXCL9 is produced by macrophages and

422 other cell types in response to interferon-gamma and typically reflects activation of the Th1  
423 pathway<sup>36</sup>. Increased plasma CXCL9 has been shown previously in GCA and is associated  
424 with CXCR3+ cell infiltration into diseased arteries<sup>37</sup>. Previous studies speculated that TAK  
425 and GCA differ in the susceptibility of T-cell pathways to glucocorticoids whereby Th1  
426 responses persist in GCA and Th17 responses persist in TAK after treatment initiation<sup>38,39</sup>.  
427 Our observation that CXCL9 was exclusively increased in GCA while IL17A was exclusively  
428 increased in TAK may support this theory.

429  
430 Beyond comparing LVV types, this study provided several disease-specific insights. We  
431 identified novel markers of active disease in TAK and in LV-GCA. Disease activity assessment  
432 is challenging in LVV, where inflammatory markers such as CRP may not correspond to  
433 disease activity detected in radiological or histopathological examination<sup>7,40</sup>. Further  
434 exploration within TAK patients identified six proteins more strongly associated with ITAS2010  
435 score than CRP, and we show that their use would provide more sensitive detection of active  
436 disease. Importantly, we also found that many proteins remained altered in TAK and LV-GCA  
437 patients despite remission. OSM and AXIN1 were elevated regardless of activity, disease  
438 duration or treatment withdrawal. Activity markers like S100A12 and VEGFA were highest in  
439 active disease but remained increased in inactive disease. These findings likely reflect  
440 persistent low-grade inflammation and are analogous to the residual molecular signatures  
441 previously described in a multi-omic study of remission in rheumatoid arthritis<sup>41</sup>. However,  
442 whether persistent molecular abnormalities impact clinically important outcomes remains  
443 unknown.

444  
445 Our results suggest that biopsy-positive and negative C-GCA are proteomically distinct. There  
446 are two possibilities that could explain our findings. First, despite a careful clinical phenotyping  
447 algorithm which included external expert review, there may be instances of misclassification  
448 within the TAB- C-GCA group, such that some patients were erroneously labelled as C-GCA.  
449 However, this cannot fully explain our findings since the TAB- C-GCA group included some  
450 patients with a positive USS. Alternatively, TAB positivity may reflect the burden of arterial  
451 disease. Skip lesions, with discontinuous segments of arterial inflammation, can occur in GCA  
452 and so a patient with lower burden of arterial disease is more likely to have a negative biopsy  
453 on the small biopsy section of artery sampled. Thus, it is possible that the proteomic read-out  
454 may reflect quantitative differences in the extent of arteritis. Our clinical lab data provided  
455 additional evidence of differences between TAB+ and TAB- patients, with higher ESR, CRP  
456 and platelet count in the former group, in keeping with previous studies<sup>42-44</sup>. Other clinical  
457 differences in TAB+ and TAB- C-GCA have been described, including greater risk of visual  
458 loss<sup>44,45</sup> and higher prevalence of PMR in TAB+ patients<sup>42</sup>, although these findings have not

459 replicated in all case series<sup>46</sup>. Our data support the concept that C-GCA can be stratified by  
460 biopsy into biologically distinct endotypes, which may have potential implications for future trial  
461 design and precision medicine strategies.

462

463 Our study had certain limitations. We used a targeted proteomic panel enriched for  
464 inflammatory and vascular proteins and thus our ability to compare between LVV groups is  
465 limited to the proteins measured. The HCs in Cohort 1 were well-matched to TAK patients but  
466 were younger than LV-GCA patients. Differences in study design between Cohort 1 and  
467 Cohort 2 mean that proteomic differences between C-GCA and the other LVV groups may be  
468 confounded by differences in disease duration and treatment history. In addition, the controls  
469 in Cohort 2 (“Not GCA”) were individuals who presented with symptoms for which a diagnosis  
470 of C-GCA was considered but ultimately excluded, whereas the controls in Cohort 1 were  
471 healthy participants with no symptoms. In Cohort 1, there was heterogeneity in treatment, with  
472 varying use of steroids and other immunosuppressants which could potentially impact the  
473 plasma proteome. However, treatment (particularly glucocorticoid dose) is given in response  
474 to disease activity, reflected in the correlation between disease activity scores and  
475 prednisolone dose in Cohort 1. Thus attempting to statistically adjust for treatment risks over-  
476 adjustment<sup>47,48</sup>. Finally, in the case of membrane-bound proteins that undergo cleavage to  
477 produce a soluble form, it is not always clear whether plasma protein measurements are  
478 exclusively capturing the latter or also protein from cell membranes (for example, arising from  
479 *in vivo* sources such as exo-/ectosomes or *ex vivo* processes such as venepuncture or sample  
480 processing), complicating interpretation.


481

482 In conclusion, similarities in the plasma proteomic profiles of active TAK and GCA indicate  
483 common effector pathways resulting in inflammatory arterial damage despite differences in  
484 genetic aetiology. Our integrated analysis of plasma and arterial tissue highlight the role  
485 played by macrophages and their protein products in LVV and indicate significant potential for  
486 their targeting in novel treatments and biomarkers. Future work should expand the molecular  
487 characterisation of the LVV disease spectrum by extending the number of proteins measured  
488 via use of complementary proteomic platforms and by concurrent measurement of other -omic  
489 layers (e.g. RNA-seq of immune cells). Longitudinal studies characterising the temporal  
490 changes in the molecular profile across the disease course will be valuable in delineating acute  
491 from chronic changes and allowing intra-individual assessment of putative biomarkers  
492 identified here.

493 **Main Figures**

**Cohort 1**


**Cohort 2**



494

495 **Figure 1. Study Overview.**

496 *Schematic overview of study to investigate the plasma proteomic changes associated with each form*  
 497 *of large vessel vasculitis in two independent cohorts. Cohort 1: patients with established Takayasu*  
 498 *arteritis (TAK) and large vessel giant cell arteritis (LV-GCA) and healthy control (HC) participants.*  
 499 *Cohort 2: patients presenting with possible cranial giant cell arteritis who subsequently had diagnosis*  
 500 *confirmed (C-GCA) or ruled out (Not C-GCA). Disease-specific proteomic profiles defined by differential*  
 501 *abundance analysis were compared. Network-based analysis of LVV-associated proteins and*  
 502 *integrated analysis with published tissue and cell-type datasets was also conducted.*




503

504 **Figure 2. Plasma proteomic changes in TAK and LV-GCA compared to Healthy Control**  
 505 **participants**

506 *Volcano plots showing results of differential protein abundance analyses: A) Takayasu Arteritis patients*  
 507 *(TAK, N=96) vs healthy controls (HC, N=35) B) Large Vessel Giant Cell Arteritis (LV-GCA, N=35) vs*  
 508 *HC.  $-\log_{10}(P_{adj}) = -\log_{10}$  Benjamini-Hochberg adjusted p-value. Red and blue indicate proteins that are*  
 509 *significantly ( $P_{adj} < 0.05$ ) upregulated and downregulated, respectively. C) Venn diagram showing the*  
 510 *overlap in proteins significantly altered in TAK vs HC compared to LV-GCA vs HC analyses. D)*  
 511 *Comparison of  $\log_2$  fold changes in all proteins for TAK vs HC and LV-GCA vs HC analyses, diagonal*  
 512 *lines represent line of identity and  $\pm 0.5 \log_2$  fold change. Blue = proteins significant in both analyses;*  
 513 *orange = significant only in TAK vs HC; teal = significant only in LV-GCA vs HC; grey = non-significant*  
 514 *in both analyses. E) Violin plots showing scaled protein levels (as Z-scores) for example proteins with*  
 515 *prominent changes in both TAK and LV-GCA.  $P_{adj} < 0.05$ : \*,  $P \leq 0.01$ : \*\*,  $P \leq 0.001$ : \*\*\*,  $P \leq 0.0001$ :*  
 516 *\*\*\*\*.*






517

518 **Figure 3. Proteins associated with active disease within TAK and LV-GCA patients**

519 *A) Points indicating log<sub>2</sub> fold changes and standard error (horizontal bars) for proteins that were*  
 520 *significantly (adjusted  $P < 0.05$ ) differentially abundant in the active vs inactive patient analysis for*  
 521 *Takayasu Arteritis only (TAK,  $N=56$  vs  $N=40$ ) (top panel), both diseases (middle panel) and Large*  
 522 *Vessel Giant Cell Arteritis only (LV-GCA,  $N=11$  vs  $N=24$ ) (bottom panel). B) Functional categories of*  
 523 *differentially abundant proteins from TAK and LV-GCA activity analyses. Violin plots depict the scaled*  
 524 *abundance values (Z-scores) for proteins associated with disease activity in both diseases (C) and for*  
 525 *the proteins which had divergent associations with disease activity in TAK and LV-GCA (D & E). P-*  
 526 *values adjusted using Benjamini-Hochberg method; No symbol: non-significant, adjusted  $P < 0.05$ ; \*,  $P$*   
 527  *$\leq 0.01$ ; \*\*,  $P \leq 0.001$ ; \*\*\*.*




528  
529 **Figure 4. Proteomic changes associated with C-GCA are most pronounced in biopsy**  
530 **proven disease**

531 *A) Volcano plots for the differential protein abundance comparisons of Cranial Giant Cell Arteritis (C-*  
532 *GCA, N=150) cases vs Not C-GCA cases (N=89) and B) for the comparison of temporal artery biopsy*  
533 *positive C-GCA (C-GCA TAB+, N=56) versus Not C-GCA (N=89).  $-\log_{10}(P_{adj}) = -\log_{10}$  Benjamini-*  
534 *Hochberg adjusted p-value. Red and blue indicate proteins that are significantly ( $P_{adj} < 0.05$ )*  
535 *upregulated and downregulated, respectively. C) Boxplot showing comparison of C-reactive protein*  
536 *(CRP), erythrocyte sedimentation rate (ESR) and platelet count between Not C-GCA, C-GCA TAB+*  
537 *and C-GCA TAB- patients. Median and IQR represented by line and box edges respectively, upper*  
538 *whisker represents the upper quartile plus 1.5 times the IQR, lower whisker represents lower quartile*  
539 *minus 1.5 times IQR. Statistical comparisons made with Kruskal-Wallis and Dunn's post-hoc tests. D)*  
540 *Comparison of  $\log_2$  fold changes for differentially abundant proteins in C-GCA TAB+ vs Not C-GCA and*  
541 *C-GCA TAB- vs Not C-GCA. E) Functional categories of differentially abundant proteins in C-GCA TAB+*  
542 *vs Not C-GCA comparison. F) Violin plots showing scaled protein levels (Z-score) for example proteins*

543 with prominent changes in C-GCA TAB+ cases. NS: non-significant, adjusted  $P < 0.05$ ; \*,  $P \leq 0.0001$ :

544 \*\*\*\*.




545

546 **Figure 5. Comparison of active TAK, LV-GCA and biopsy-proven C-GCA proteomic**  
 547 **profiles**

548 *A) Heatmap showing  $\log_2$  fold changes (FC) of the 112 differentially abundant proteins (DAP) identified*  
 549 *in active Takayasu Arteritis (TAK) vs healthy control (HC), active Large Vessel Giant Cell Arteritis (LV-*  
 550 *GCA) vs HC and temporal artery biopsy positive (TAB+) C-GCA vs Not C-GCA comparisons. Left: navy*  
 551 *boxes represent proteins with statistically significant changes (Adjusted  $P < 0.05$ ) in each disease.*  
 552 *Right: annotated functional category for each protein. B) Disease to disease comparison of  $\log_2$  FC for*  
 553 *112 DAP, diagonal lines represent the line of identity. Network plots of (C), known protein-protein*

554 interactions and (D), protein-protein co-expression for proteins with concordant changes in each  
555 disease (74). Node size corresponds to the number of connections to other nodes. For C, high  
556 confidence interactions ( $\geq 0.9$ ) were sourced from STRING<sup>20</sup> and for D, protein co-expression was  
557 defined as a Pearson correlation  $\geq 0.6$  in both active TAK/LV-GCA patients and TAB+ C-GCA patients.  
558 E) Violin plots showing scaled abundance values (Z-scores) for selected proteins associated with active  
559 TAK and LV-GCA but not C-GCA (F) and those identified as different between active LV-GCA and C-  
560 GCA vs active TAK. P-values adjusted using Benjamini-Hochberg method; No symbol: non-significant,  
561 Adjusted  $P < 0.05$ : \*,  $P \leq 0.01$ : \*\*,  $P \leq 0.001$ : \*\*\*,  $P \leq 0.0001$ : \*\*\*\*.



562

563 **Figure 6. Correspondence of LVV plasma profile to arterial tissue phenotype**

564 *Comparison of plasma proteomic profiles associated with LVV and gene expression changes identified*  
 565 *in aortic tissue affected by large vessel vasculitis (LVV)<sup>21</sup>. A) Pie chart showing the proportion of 112*  
 566 *LVV-associated plasma proteins (Table S16) that were also differentially expressed (Adjusted P < 0.05)*  
 567 *in the comparison of large vessel giant cell arteritis (LV-GCA) related aortic aneurysm (N=8) to non-*  
 568 *inflammatory aortic aneurysm (NI-AA) by bulk RNA-seq (N=25). B) Comparison of plasma protein and*  
 569 *aortic gene expression log<sub>2</sub> fold changes (Log<sub>2</sub>FC) for the 47 proteins and corresponding genes that*  
 570 *had significant changes in both LVV plasma and aortic tissue, each point represents a gene/protein*  
 571 *pair. For proteomics, Log<sub>2</sub>FCs represent active Takayasu Arteritis (TAK) vs healthy control (HC), active*  
 572 *LV-GCA vs HC and temporal artery biopsy positive cranial-GCA (TAB+ C-GCA) vs Not C-GCA*  
 573 *comparisons. For transcriptomics, Log<sub>2</sub>FCs represent LV-GCA associated aortitis vs NI-AA. (C-E), Dot*  
 574 *plots showing aortic gene expression of genes/proteins DA in both LVV plasma and aortic tissue. Genes*  
 575 *proteins typically expressed by macrophages (C), non-haematopoietic stromal cells (D) and*  
 576 *lymphocytes (E). Gene expression measured in transcripts per million (TPM), cell-type expression*  
 577 *classified using blueprint data (Figure S8). P-values were adjusted using Benjamini-Hochberg method.*

578 **Tables**

579

580 **Table 1: TAK and LV-GCA cohorts**

	<b>HC</b>	<b>TAK</b>	<b>LV-GCA</b>
N	35	96	35
Female (%)	31 (88.6)	91 (94.8)	28 (80)
Age (years)	38.2 [30.4, 52.5]	41.6 [30.9, 55.6]	67.2 [61.3, 72.3]
Ethnicity			
White European (%)	21 (60)	55 (57.3)	30 (85.7)
Asian (%)	11 (31.4)	35 (36.5)	4 (11.4)
Other (%)	3 (8.6)	6 (6.3)	1 (2.9)
Time since diagnosis, yrs	-	3.9 [1.1, 10.3]	1.4 [0.5, 3.7]
Active Disease (%)*	-	56 (58.3)	11 (31.4)
CRP >5mg/L (%)	-	42 (43.7)	17 (48.6)
ESR >20mm/hr (%)	-	59 (61.5)	17 (48.6)
Treatment			
No treatment (%)	-	21 (21.9)	6 (17.1)
Time on Treatment	-	2.6 [0.7, 7.4]	1.4 [0.5, 4.1]
Glucocorticoids (%)	-	62 (64.6)	28 (80)
csDMARD (%)	-	57 (59.4)	18 (51.4)
Biologic (%)	-	7 (7.3)	1 (2.8)

581 *Data is median [IQR] or N (%) where indicated. \*For Takayasu Arteritis patients (TAK), active disease:*  
582 *ITAS2010 score  $\geq 1$  or ITAS.CRP  $\geq 2$ ; for large vessel giant cell arteritis patients (LV-GCA): NIH score*  
583  *$\geq 2$  at the time of sampling. CRP, C-reactive protein; ESR, erythrocyte sedimentation rate. Treatment*  
584 *at time of sampling is summarised. csDMARD, conventional synthetic disease modifying anti-rheumatic*  
585 *drug; Biologic, targeted biologic agent e.g. anti-IL6R monoclonal antibodies or TNF inhibitor.*

586 **Table 2: C-GCA cohort**

	<b>Not C-GCA</b>	<b>C-GCA</b>
N	89	150
Age	69 [62, 76]	73.5 [67, 78]
Female (%)	63 (70.8)	108 (72)
White European (%)	88 (98.9)	149 (99.3)
TAB+ (%) <sup>*</sup>	0 (0)	56 (37.3)
USS Positive (%)	27 (30.3)	78 (52)
Cranial Ischaemic Complications (%)	18 (20.2)	33 (22)
Polymyalgic symptoms (%)	7 (7.9)	18 (12)
ESR, mm/hr <sup>†</sup>	13 [5, 28]	35 [19.5, 58]
CRP, mg/L <sup>†</sup>	14 [4, 22.5]	30 [12.7, 54]
Platelets, 10 <sup>9</sup> /L <sup>†</sup>	290 [236, 332]	348 [277, 454]

587 *Data is median [IQR] or N (%) where indicated. \*Six patients did not have TAB result available. †Only*  
 588 *partial data available: Not C-GCA N = 81, 55, 89 for ESR, CRP and platelets respectively; C-GCA N =*  
 589 *143, 98, 147. TAB, temporal artery biopsy; USS, temporal artery ultrasound sonography; Cranial*  
 590 *Ischaemic Complications (as per methods); ESR, erythrocyte sedimentation rate; CRP, C-reactive*  
 591 *protein.*

## 592 **Methods**

### 593 **Cohort 1 study participants**

594 Patients with TAK or LV-GCA were recruited from the Hammersmith Hospital (Imperial College  
595 Healthcare NHS Trust, UK) between 2013 and 2020. TAK patients fulfilled EULAR/ACR 2022  
596 classification criteria<sup>23</sup> and all had typical patterns of arterial involvement in radiological assessments.  
597 LV-GCA patients were >50 years at onset with radiological evidence of LVV, as defined previously<sup>13</sup>.  
598 Three LV-GCA patients had concurrent temporal artery involvement (confirmed by temporal artery USS  
599 and/or TAB). HC participants were recruited locally from hospital and college staff and had no history  
600 of inflammatory or cardiovascular disease. Citrate blood samples were centrifuged at 1000G for 10  
601 minutes within 4 hours of venepuncture and plasma was stored at -80°C until use. Disease activity was  
602 assessed using the Indian Takayasu Clinical Activity Score (ITAS2010) for TAK<sup>15</sup> and the National  
603 Institutes of Health (NIH) score for LV-GCA<sup>40</sup>. Active disease was defined as ITAS2010 score  $\geq 1$  or  
604 ITAS-CRP  $\geq 2$  for TAK and NIH score  $\geq 2$  for LV-GCA. All inactive cases were retrospectively confirmed  
605 to be relapse free for 1 year following sample collection. Patients and HC provided written informed  
606 consent, and samples were collected as a sub-collection registered with the Imperial College Healthcare  
607 Tissue Bank (licence: 12275; National Research Ethics Service approval 17/WA/0161).

### 608 **Cohort 2 study participants**

609 The Temporal Artery Biopsy vs Ultrasound in Diagnosis of GCA (TABUL) was an international,  
610 multicentre, prospective study which compared the sensitivity and specificity of temporal artery  
611 ultrasound to biopsy in 381 patients with suspected C-GCA<sup>16</sup> [ClinicalTrials.gov: NCT00974883].  
612 Reference diagnosis of C-GCA or Not C-GCA at 6 months was based on a combination of baseline  
613 signs and symptoms, blood tests, TAB, fulfilment of ACR 1990 GCA classification criteria, clinical course  
614 during the follow-up period, final consultant diagnoses and verification by an expert review panel, as  
615 described previously<sup>16</sup>.

616 Cranial ischaemic complications were defined as permanent ocular or non-ocular conditions at  
617 presentation. Ocular complications: anterior ischaemic optic neuropathy, branch retinal artery  
618 occlusion, cilioretinal artery occlusion, cranial nerve palsy (III, IV or V), central retinal artery occlusion,  
619 posterior ischaemic optic neuropathy relative afferent pupillary defect; irreversible visual loss;  
620 irreversible visual field defect; irreversible ocular motility or irreversible diplopia. Non-ocular cranial  
621 complications: scalp necrosis; tongue necrosis; cerebrovascular accident at presentation considered  
622 secondary to GCA). Polymyalgic symptoms at presentation are also reported but do not represent a  
623 confirmed diagnosis of polymyalgia rheumatica.

624 Citrated blood samples collected as soon as feasible after starting glucocorticoid treatment (median  
625 [IQR] 2 [1-4]) and were centrifuged at 2500 G for 15 minutes within 1.5 hours of collection and plasma  
626 was stored at -80°C until use. Due to funding constraints and biosample availability, we performed Olink  
627 proteomic assays on 239 patient samples out of the 381 patients recruited to TABUL. We included all  
628 available samples from patients with a diagnosis of C-GCA. We selected a subset of sex and age (+/  
629 5 years) matched Not C-GCA cases such that the ratio of C-GCA to Not C-GCA was approximately 2:1.  
630 As part of the study design, we selected an equal proportion of cases with cranial ischaemic



631 complications in the C-GCA group as in the Not C-GCA group. Overall study approval was granted by  
632 the Berkshire Research Ethics Committee (09/H0505/132) and approved was also granted at local  
633 participating clinical sites.

634

### 635 **Proteomic analysis**

636 184 proteins were measured by proximity extension assay using two Olink Target panels, 'Inflammation  
637 1' and 'Cardiometabolic' at the Leeds Immunogenomics Facility, University of Leeds. In order to provide  
638 a succinct and standardised nomenclature, we report proteins by the symbols of the genes encoding  
639 them (see **Table S3** for a full list of proteins and associated full names and accession numbers). Cohort  
640 1 and 2 samples were processed and analysed independently, but proteomic measurements were  
641 performed in the same facility. We designed assay plates such that samples were balanced across  
642 plates according to disease grouping and disease activity status, with randomisation to determine well  
643 position within plates. Proteomic data were normalised using standard Olink workflows, which includes  
644 inter-plate normalisation, to produce measures of relative protein abundance ('NPX') (log<sub>2</sub> scale). For  
645 visualisation, we transformed to Z-scores (mean=0, SD=1). Due to a technical fault with a PCR machine  
646 during the running of one plate on the Inflammation 1 panel for Cohort 2, it was necessary to re-run this  
647 plate as a separate batch. Principal component analysis (PCA) revealed a batch effect, with samples  
648 from this plate separated from samples on the other three plates run as part of the first batch. We  
649 therefore adjusted for this batch effect for proteins measured on the Inflammation 1 panel in Cohort 2,  
650 using batch (a binary variable) as a covariate in linear model based differential abundance analyses.  
651 For situations requiring batch-correction outside of differential abundance testing (e.g. visualisation of  
652 protein levels using violin plots and heatmaps and network analyses), the residuals from the linear  
653 model (in Wilkinson notation)  $NPX \sim \text{Batch}$  were used to generate batch-corrected protein values.  
654 Further PCA of these residuals confirmed that the batch effect had been removed. The residuals were  
655 then converted to Z scores prior to visualisation or other downstream analyses. Cardiometabolic panels  
656 for Cohort 1 were not affected by this issue and were analysed as a single batch.

657 Proteins with >75% of samples below the lower limit of detection were removed resulting in 158 and  
658 167 protein measurements for Cohort 1 and 2, respectively. Sample-level QC was performed using  
659 internal assay controls, boxplots of relative protein abundance values and PCA for outlier detection. In  
660 Cohort 1, three samples (1 HC and 2 TAK) were excluded from Inflammation panel measurements due  
661 to amplification failures. In Cohort 2, fifteen samples (9 C-GCA and 6 Not C-GCA) were excluded from  
662 Inflammation panel and 3 (all C-GCA) from the Cardiometabolic panel measurements due to  
663 amplification failures and flagged status in internal QC checks. Wherever possible all available data  
664 was analysed (e.g. differential abundance analyses) but some analyses (e.g. hierarchical clustering,  
665 PCA, multiple linear regression versus clinical parameters) necessitated using only complete data. The  
666 final post-QC datasets are provided on figshare: [10.6084/m9.figshare.26928211](https://figshare.com/10.6084/m9.figshare.26928211).

667 Differential protein abundance was performed using linear models in R. For a given protein, protein  
668 abundance was regressed on disease status (encoded as 0 or 1). The beta coefficient for the disease  
669 status term represents the estimated log<sub>2</sub> fold change in the protein level between groups under

670 comparison. For example, for the analysis of TAK versus HCs, the regression model was  $NPX \sim D$ ,  
671 where NPX was  $\log_2$  protein level (continuous variable) and D was a binary variable, encoded as 0 for  
672 HC and 1 for TAK. Correction for multiple testing (multiple proteins) was performed using the Benjamini-  
673 Hochberg method and an adjusted P-value of  $< 0.05$  (i.e. false discovery rate  $< 5\%$ ) was defined as  
674 significant.

### 675 **Protein annotation**

676 Olink panel proteins were manually classified as “Cytokine Related”, “Growth Factor Related”,  
677 “Chemokine, Other Immune/Inflammatory related protein”, “Extracellular matrix Related” or “Other  
678 Function” for the purpose of the annotation of differential abundance results. This was done using a  
679 combination of public resources including Gene Ontology terms, pathway and functional databases.  
680 The full list of proteins and associated classifications is provided in **Table S3**.

### 681 **Network analysis**

682 The protein-protein interaction network between differentially abundant proteins was constructed using  
683 high confidence interactions (confidence  $\leq 0.9$ ) sourced from STRING<sup>20</sup>. No additional filtering of  
684 interactions was performed. The protein co-expression network of differentially abundant proteins was  
685 created using inter-protein correlation. Node edges were defined as Pearson  $r \geq 0.6$ . Cohort 1 (TAK  
686 and LV-GCA) and Cohort 2 (C-GCA) networks were computed individually and then intersected so that  
687 only correlations present in both networks feature in the final network. Both networks were plotted using  
688 the igraph package in R<sup>49</sup>.

### 689 **Tissue expression of differentially abundant proteins**

690 GTEx bulk RNA-seq tissue expression data was accessed as median transcript per million values per  
691 tissue<sup>18</sup>. Data pre-processing included: removal of sex-specific organ data (i.e. cervix, breast, vagina,  
692 testis, fallopian tubes), removal of purified cell data (e.g. cultured fibroblasts) and where there were  
693 multiple sample types per tissue group (e.g. Artery-Coronary or Artery-Aorta) the highest expression  
694 value was used for that tissue type. Enhanced tissue expression of differentially abundant proteins was  
695 defined as  $>4$  fold higher than the averages expression in other tissues as done previously by the  
696 Human Protein Atlas<sup>19</sup>.

### 697 **RNA-seq analysis of LVV arterial tissue**

698 A previous study compared the transcriptomic profile of inflammatory and non-inflammatory aortic  
699 aneurysms using bulk RNA-seq<sup>21</sup>. Gene-level count data was accessed and filtered for cases of  
700 inflammatory aneurysm associated with GCA (n=8) for comparison with non-inflammatory cases  
701 (n=25). Data was normalised, genes with low expression were removed and groups were compared  
702 using the standard edgeR package methodology<sup>50</sup>. Differentially expressed (DE) genes were defined  
703 using Benjamini Hochberg adjusted  $P < 0.05$ . DE genes were then compared with LVV-associated  
704 plasma proteins with regards to overlap and Pearson correlation of  $\log_2$  fold change in each disease.

### 705 **Other analyses**

706 Details of additional analyses are provided in [Supplemental Information File](#).

707 **Data availability**

708 Individual-level normalised post-QC proteomic data are provided on figshare:  
709 [10.6084/m9.figshare.26928211](https://doi.org/10.6084/m9.figshare.26928211)

710

711 **Acknowledgments**

712 We thank Prof. Marina Botto and Prof. Matthew Pickering for helpful comments on the  
713 manuscript. We thank the patients and healthy volunteers who participated in this study, along  
714 with the clinical research teams who recruited patients. We thank Surjeet Singh as the chief  
715 study coordinator for TABUL, and Bhaskar Dasgupta as a co-investigator on TABUL who  
716 played a leading role in the study recruitment. Prof Mason tragically passed away during the  
717 study and we dedicate this paper to his memory.

718 **Sources of Funding**

719 This study was funded in part by the Medical Research Council (MRC) "Treatment According  
720 to Response in Giant cell Arteritis" (TARGET) Partnership award, Medical Research  
721 Foundation (MRF-042-0001-RG-PETE-C0839), Vasculitis UK (V2105), MRC Confidence in  
722 Concept (Leeds), the NIHR Imperial Biomedical Research Centre (BRC), and the NIHR Leeds  
723 BRC. The TABUL study was funded via an NIHR Health Technology Assessment grant. N.C.  
724 was supported by an MRC DiMen award. CP was supported by Versus Arthritis (Career  
725 Development Fellowship, 21223) and Imperial College -Wellcome Trust Institutional Strategic  
726 Support Fund (ISSF). J.E.P. is supported by a Medical Research Foundation Fellowship  
727 (MRF-057-0003-RG-PETE-C0799). A.W.M. is an NIHR Senior Investigator and supported by  
728 the NIHR Leeds BRC and was previously supported by the NIHR Leeds MedTech and Invitro  
729 Diagnostics Co-operative and MRC TARGET Partnership grant. The views expressed are  
730 those of the authors and not necessarily those of the NIHR or the Department of Health and  
731 Social Care.

732 **Disclosures**

733 J.E.P. has received travel and accommodation expenses to speak at Olink-sponsored  
734 academic meetings (none in the last 5 years). C.P. is a recipient of a research grant from  
735 Galapagos BV; unrelated this study. A.W.M. previously received a research grant from Roche  
736 PLC, for unrelated work, and has undertaken consultancy or received honoraria for speaking  
737 at educational events on behalf of her institution from AstraZeneca, Roche and Vifor in the  
738 last 5 years. R.A.L has served on advisory boards for GSK and Roche; has received  
739 assistance to attend meetings from CSL Vifor; has received grants from Roche, Celgene/BMS  
740 and CSL Vifor, and has participated in clinical trials for Roche, GSK, Novartis, and InflaRx.

741

742 **Supplemental Material**

743 [Supplementary Information File.docx](#)

744 Supplementary Methods

745 Figure S1: Comparing TAK findings to those of a previous plasma proteomic study

746 Figure S2: TAK and LV-GCA vs HC comparison

747 Figure S3: Plasma protein differences between TAK and LV-GCA patients

748 Figure S4: Proteins associated with Disease Activity Score in TAK

749 Figure S5: Differentially abundant proteins in inactive TAK & LV-GCA

750 Figure S6: Proteomic changes in C-GCA are most pronounced in biopsy proven disease

751 Figure S7: Comparison of proteomic changes in TAB+ and TAB- C-GCA patients

752 Figure S8: Comparing biopsy proven C-GCA findings to those of a previous plasma proteomic  
753 study

754 Figure S9: Tissue expression of LVV-associated plasma proteins

755 Figure S10: Cell-type expression profile of proteins/genes identified as dysregulated in both  
756 LVV plasma and tissue

757  
758 [Supplementary Data File.xlsx](#)

759 Table S1: Proteins measured in this study

760 Table S2: Characteristics of TAK and LV-GCA patients with inactive and active disease

761 Table S3: Differential protein abundance analysis TAK vs HC

762 Table S4: Differential protein abundance analysis LV-GCA vs HC

763 Table S5: Differential protein abundance analysis TAK vs LV-GCA

764 Table S6: Differential protein abundance analysis Active TAK vs Inactive TAK

765 Table S7: Differential protein abundance analysis Active LV-GCA vs Inactive LV-GCA

766 Table S8: Differential protein abundance analysis Inactive TAK vs HC

767 Table S9: Differential protein abundance analysis Inactive LV-GCA vs HC

768 Table S10: Differential protein abundance analysis C-GCA vs Not C-GCA

- 769 Table S11: Differential protein abundance analysis C-GCA TAB+ vs Not C-GCA
- 770 Table S12: Differential protein abundance analysis C-GCA TAB- vs Not C-GCA
- 771 Table S13: Characteristics of Not C-GCA cases and C-GCA patients stratified by TAB result
- 772 Table S14: Differential protein abundance analysis Active TAK vs HC
- 773 Table S15: Differential protein abundance analysis Active LV-GCA vs HC
- 774 Table S16: Comparison of active TAK, active LV-GCA and C-GCA TAB+ proteomic profiles
- 775 Table S17: Proteins & Genes dysregulated in both LVV plasma and arterial tissue
- 776 *Note, Tables S2 and S13 are also provided in the supplementary information file for*
- 777 *convenience.*

## 778 **References**

- 779 1. Pugh D, Karabayas M, Basu N, Cid MC, Goel R, Goodyear CS, et al. Large vessel  
780 vasculitis. *Nat Rev Dis Primer*. 2022 Jan 6;7(1):93.
- 781 2. Koster MJ, Matteson EL, Warrington KJ. Large-vessel giant cell arteritis: diagnosis,  
782 monitoring and management. *Rheumatology*. 2018 Feb 1;57(suppl\_2):ii32–42.
- 783 3. Gribbons KB, Ponte C, Carette S, Craven A, Cuthbertson D, Hoffman GS, et al. Patterns  
784 of Arterial Disease in Takayasu Arteritis and Giant Cell Arteritis. *Arthritis Care Res*.  
785 2020;72(11):1615–24.
- 786 4. Grayson PC. Lumpers and Splitters: Ongoing Issues in the Classification of Large Vessel  
787 Vasculitis. *J Rheumatol*. 2015 Feb 1;42(2):149–51.
- 788 5. Maksimowicz-McKinnon K, Clark TM, Hoffman GS. Takayasu arteritis and giant cell  
789 arteritis: a spectrum within the same disease? *Medicine (Baltimore)*. 2009 Jul;88(4):221–  
790 6.
- 791 6. Watanabe Y, Miyata T, Tanemoto K. Current Clinical Features of New Patients With  
792 Takayasu Arteritis Observed From Cross-Country Research in Japan. *Circulation*. 2015  
793 Nov 3;132(18):1701–9.
- 794 7. Tombetti E, Hysa E, Mason JC, Cimmino MA, Camellino D. Blood Biomarkers for  
795 Monitoring and Prognosis of Large Vessel Vasculitides. *Curr Rheumatol Rep*. 2021 Feb  
796 10;23(3):17.
- 797 8. O'Connor TE, Carpenter HE, Bidari S, Waters MF, Hedna VS. Role of inflammatory  
798 markers in Takayasu arteritis disease monitoring. *BMC Neurol*. 2014 Mar 28;14:62.
- 799 9. Broder MS, Sarsour K, Chang E, Collinson N, Tuckwell K, Napalkov P, et al.  
800 Corticosteroid-related adverse events in patients with giant cell arteritis: A claims-based  
801 analysis. *Semin Arthritis Rheum*. 2016 Oct 1;46(2):246–52.
- 802 10. Pujades-Rodriguez M, Morgan AW, Cubbon RM, Wu J. Dose-dependent oral  
803 glucocorticoid cardiovascular risks in people with immune-mediated inflammatory  
804 diseases: A population-based cohort study. *PLOS Med*. 2020 Dec 3;17(12):e1003432.
- 805 11. Joshi A, Rienks M, Theofilatos K, Mayr M. Systems biology in cardiovascular disease: a  
806 multiomics approach. *Nat Rev Cardiol*. 2021 May;18(5):313–30.
- 807 12. Cui X, Qin F, Song L, Wang T, Geng B, Zhang W, et al. Novel Biomarkers for the  
808 Precise Diagnosis and Activity Classification of Takayasu Arteritis. *Circ Genomic Precis  
809 Med*. 2019 Jan;12(1):e002080.
- 810 13. Stone JH, Tuckwell K, Dimonaco S, Klearman M, Aringer M, Blockmans D, et al. Trial of  
811 Tocilizumab in Giant-Cell Arteritis. *N Engl J Med*. 2017 Jul 27;377(4):317–28.
- 812 14. Robinette ML, Rao DA, Monach PA. The Immunopathology of Giant Cell Arteritis Across  
813 Disease Spectra. *Front Immunol [Internet]*. 2021 Feb 25 [cited 2024 Jul 11];12. Available  
814 from:  
815 [https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.623716/fu](https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2021.623716/full)  
816 ll

- 817 15. Misra R, Danda D, Rajappa SM, Ghosh A, Gupta R, Mahendranath KM, et al.  
818 Development and initial validation of the Indian Takayasu Clinical Activity Score  
819 (ITAS2010). *Rheumatol Oxf Engl*. 2013 Oct;52(10):1795–801.
- 820 16. Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, et al. The Role of  
821 Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of  
822 Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study. *Health*  
823 *Technol Assess Winch Engl*. 2016 Nov;20(90):1–238.
- 824 17. Burja B, Feichtinger J, Lakota K, Thallinger GG, Sodin-Semrl S, Kuret T, et al. Utility of  
825 serological biomarkers for giant cell arteritis in a large cohort of treatment-naïve patients.  
826 *Clin Rheumatol*. 2019 Feb 1;38(2):317–29.
- 827 18. Lonsdale J, Thomas J, Salvatore M, Phillips R, Lo E, Shad S, et al. The Genotype-Tissue  
828 Expression (GTEx) project. *Nat Genet*. 2013 Jun;45(6):580–5.
- 829 19. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Tissue-  
830 based map of the human proteome. *Science*. 2015 Jan 23;347(6220):1260419.
- 831 20. Szklarczyk D, Kirsch R, Koutrouli M, Nastou K, Mehryary F, Hachilif R, et al. The STRING  
832 database in 2023: protein-protein association networks and functional enrichment  
833 analyses for any sequenced genome of interest. *Nucleic Acids Res*. 2023 Jan  
834 6;51(D1):D638–46.
- 835 21. Hur B, Koster MJ, Jang JS, Weyand CM, Warrington KJ, Sung J. Global Transcriptomic  
836 Profiling Identifies Differential Gene Expression Signatures between Inflammatory and  
837 Non-inflammatory Aortic Aneurysms. *Arthritis Rheumatol Hoboken NJ*. 2022  
838 Aug;74(8):1376–86.
- 839 22. Fernández JM, de la Torre V, Richardson D, Royo R, Puiggròs M, Moncunill V, et al. The  
840 BLUEPRINT Data Analysis Portal. *Cell Syst*. 2016 Nov 23;3(5):491-495.e5.
- 841 23. Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A, et al. 2022  
842 American College of Rheumatology/EULAR Classification Criteria for Takayasu Arteritis.  
843 *Arthritis Rheumatol*. 2022;74(12):1872–80.
- 844 24. Ponte C, Grayson PC, Robson JC, Suppiah R, Gribbons KB, Judge A, et al. 2022  
845 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis.  
846 *Arthritis Rheumatol*. 2022;74(12):1881–9.
- 847 25. Carmona FD, Coit P, Saruhan-Direskeneli G, Hernández-Rodríguez J, Cid MC, Solans  
848 R, et al. Analysis of the common genetic component of large-vessel vasculitides through  
849 a meta-immunochip strategy. *Sci Rep*. 2017 Mar 9;7:43953.
- 850 26. Kong X, Xu M, Cui X, Ma L, Cheng H, Hou J, et al. Potential Role of Macrophage  
851 Phenotypes and CCL2 in the Pathogenesis of Takayasu Arteritis. *Front Immunol*. 2021  
852 May 17;12:646516.
- 853 27. Jiemy WF, van Sleen Y, van der Geest KS, ten Berge HA, Abdulahad WH, Sandovici M,  
854 et al. Distinct macrophage phenotypes skewed by local granulocyte macrophage colony-  
855 stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) are  
856 associated with tissue destruction and intimal hyperplasia in giant cell arteritis. *Clin*  
857 *Transl Immunol*. 2020 Aug 27;9(9):e1164.



- 858 28. Aloufi NA, Ali AK, Burke Schinkel SC, Molyer B, Barros PO, McBane JE, et al. Soluble  
859 CD127 potentiates IL-7 activity in vivo in healthy mice. *Immun Inflamm Dis*.  
860 2021;9(4):1798–808.
- 861 29. Yoon T, Pyo JY, Ahn SS, Song JJ, Park YB, Lee SW. Serum soluble interleukin-7  
862 receptor alpha levels are negatively correlated with the simultaneous activity of  
863 antineutrophil cytoplasmic antibody-associated vasculitis. *Clin Exp Rheumatol*. 2023  
864 Apr;41(4):879–86.
- 865 30. Lundtoft C, Afum-Adjei Awuah A, Rimpler J, Harling K, Nausch N, Kohns M, et al.  
866 Aberrant plasma IL-7 and soluble IL-7 receptor levels indicate impaired T-cell response  
867 to IL-7 in human tuberculosis. *PLoS Pathog*. 2017 Jun 5;13(6):e1006425.
- 868 31. Meyer A, Parmar PJ, Shahrara S. Significance of IL-7 and IL-7R in RA and autoimmunity.  
869 *Autoimmun Rev*. 2022 Jul 1;21(7):103120.
- 870 32. Ware CF, Croft M, Neil GA. Realigning the LIGHT signaling network to control  
871 dysregulated inflammation. *J Exp Med*. 2022 May 23;219(7):e20220236.
- 872 33. Shaikh RB, Santee S, Granger SW, Butrovich K, Cheung T, Kronenberg M, et al.  
873 Constitutive Expression of LIGHT on T Cells Leads to Lymphocyte Activation,  
874 Inflammation, and Tissue Destruction. *J Immunol*. 2001 Dec 1;167(11):6330–7.
- 875 34. Herro R, Croft M. The control of tissue fibrosis by the inflammatory molecule LIGHT (TNF  
876 Superfamily member 14). *Pharmacol Res*. 2016 Feb;104:151–5.
- 877 35. Golledge J, Clancy P, Maguire J, Lincz L, Koblar S. The role of tenascin C in  
878 cardiovascular disease. *Cardiovasc Res*. 2011 Oct 1;92(1):19–28.
- 879 36. Berthoud TK, Dunachie SJ, Todryk S, Hill AVS, Fletcher HA. MIG (CXCL9) is a more  
880 sensitive measure than IFN- $\gamma$  of vaccine induced T-cell responses in volunteers receiving  
881 investigated malaria vaccines. *J Immunol Methods*. 2009 Jan 1;340(1):33–41.
- 882 37. Graver JC, Abdulhad W, van der Geest KSM, Heeringa P, Boots AMH, Brouwer E, et  
883 al. Association of the CXCL9-CXCR3 and CXCL13-CXCR5 axes with B-cell trafficking in  
884 giant cell arteritis and polymyalgia rheumatica. *J Autoimmun*. 2021 Sep;123:102684.
- 885 38. Deng J, Younge BR, Olshen RA, Goronzy JJ, Weyand CM. Th17 and Th1 T-cell  
886 responses in giant cell arteritis. *Circulation*. 2010 Feb 23;121(7):906–15.
- 887 39. Saadoun D, Garrido M, Comarmond C, Desbois AC, Domont F, Savey L, et al. Th1 and  
888 Th17 cytokines drive inflammation in Takayasu arteritis. *Arthritis Rheumatol Hoboken*  
889 *NJ*. 2015 May;67(5):1353–60.
- 890 40. Kerr GS, Hallahan CW, Giordano J, Leavitt RY, Fauci AS, Rottem M, et al. Takayasu  
891 arteritis. *Ann Intern Med*. 1994 Jun 1;120(11):919–29.
- 892 41. Tasaki S, Suzuki K, Kassai Y, Takeshita M, Murota A, Kondo Y, et al. Multi-omics  
893 monitoring of drug response in rheumatoid arthritis in pursuit of molecular remission. *Nat*  
894 *Commun*. 2018 Jul 16;9:2755.
- 895 42. Koster MJ, Yeruva K, Crowson CS, Muratore F, Labarca C, Warrington KJ. Giant cell  
896 arteritis and its mimics: A comparison of three patient cohorts. *Semin Arthritis Rheum*.  
897 2020 Oct;50(5):923–9.

- 898 43. Gonzalez-Gay MA, Garcia-Porrúa C, Llorca J, Gonzalez-Louzao C, Rodriguez-Ledo P.  
899 Biopsy-negative giant cell arteritis: Clinical spectrum and predictive factors for positive  
900 temporal artery biopsy. *Semin Arthritis Rheum*. 2001 Feb 1;30(4):249–56.
- 901 44. Duhaut P, Pinède L, Bornet H, Demolombe-Ragué S, Dumontet C, Ninet J, et al. Biopsy  
902 proven and biopsy negative temporal arteritis: differences in clinical spectrum at the  
903 onset of the disease. *Ann Rheum Dis*. 1999 Jun 1;58(6):335–41.
- 904 45. Chatelain D, Duhaut P, Schmidt J, Loire R, Bosshard S, Guernou M, et al. Pathological  
905 features of temporal arteries in patients with giant cell arteritis presenting with permanent  
906 visual loss. *Ann Rheum Dis*. 2009 Jan 1;68(1):84–8.
- 907 46. Putman MS, Gribbons KB, Ponte C, Robson J, Suppiah R, Craven A, et al.  
908 Clinicopathologic Associations in a Large International Cohort of Patients With Giant Cell  
909 Arteritis. *Arthritis Care Res*. 2022 Jun;74(6):1013–8.
- 910 47. Westreich D, Greenland S. The Table 2 Fallacy: Presenting and Interpreting Confounder  
911 and Modifier Coefficients. *Am J Epidemiol*. 2013 Feb 15;177(4):292–8.
- 912 48. Schisterman EF, Cole SR, Platt RW. Overadjustment Bias and Unnecessary Adjustment  
913 in Epidemiologic Studies. *Epidemiol Camb Mass*. 2009 Jul;20(4):488–95.
- 914 49. Csárdi G, Nepusz T. The igraph software package for complex network research. In 2006  
915 [cited 2024 Jul 11]. Available from: <https://www.semanticscholar.org/paper/The-igraph-software-package-for-complex-network-Cs%C3%A1rdi-Nepusz/1d2744b83519657f5f2610698a8ddd177ced4f5c>  
916  
917
- 918 50. Chen Y, Lun ATL, Smyth GK. From reads to genes to pathways: differential expression  
919 analysis of RNA-Seq experiments using Rsubread and the edgeR quasi-likelihood  
920 pipeline. *F1000Research*. 2016 Aug 2;5:1438.
- 921